Angeline S. Andrew

Dr. Angeline S. Andrew serves as Associate Professor of Neurology at the Geisel School of Medicine, Dartmouth College, with additional affiliations in the Dartmouth Cancer Center, Program in Experimental and Molecular Medicine, and Quantitative Biomedical Sciences. Her laboratory operates at the intersection of molecular toxicology and population health sciences.

Her educational background includes a PhD from Dartmouth Medical School (2001) where she worked in the Superfund Basic Research Program studying toxic metals mechanisms, and a BS from Tufts University (1996) with double majors in Biology and Environmental Science. Postdoctoral training in molecular epidemiology at the University of Michigan School of Public Health provided expertise in research design and statistical analysis.

Dr. Andrew's research program uniquely bridges wet-lab molecular biology with population epidemiology, focusing on how environmental exposures translate to human disease outcomes. Her work examines molecular mechanisms of toxic metals while simultaneously investigating their population-level health impacts, particularly regarding neurodegenerative diseases and cancer progression. Current projects employ advanced techniques including high-throughput molecular analysis, GIS exposure assessment, and statistical modeling of complex gene-environment interactions.

Analysis of her publication record reveals a clear trajectory from fundamental molecular toxicology toward population-based environmental health research. Early work focused on nickel and arsenic mechanisms in cell culture, evolving to population studies examining mercury-ALS connections and microRNA biomarkers in bladder cancer. Her research consistently demonstrates translational impact, connecting molecular pathways to clinical outcomes through sophisticated epidemiological approaches.

Dr. Andrew maintains an active grant portfolio with multiple NIH and CDC-funded projects, including as PI on the R21CA182659 grant studying dysregulated microRNA in bladder cancer, and as Co-I on several ALS-related studies examining environmental risk factors. She directs the Molecular Biologic Markers in Human Health studies course and teaches Cancer Biology, Epidemiology I, and serves as small group leader for Epidemiology and Biostatistics courses. Her computational and wet-lab expertise supports the SYNERGY Advanced Certificate in Clinical Translational Research program.

Her laboratory develops and applies integrated methodologies spanning molecular characterization, exposure assessment, and clinical follow-up. Current projects involve GIS mapping of environmental exposures, high-throughput molecular analysis in R, and longitudinal cohort studies examining how environmental stressors interact with genetic factors to influence disease progression in ALS and bladder cancer.